PADOVAN, MARTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.032
AS - Asia 1.330
EU - Europa 614
SA - Sud America 267
AF - Africa 207
Continente sconosciuto - Info sul continente non disponibili 37
OC - Oceania 13
Totale 4.500
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.864
SG - Singapore 408
CN - Cina 227
VN - Vietnam 220
IT - Italia 161
BR - Brasile 159
HK - Hong Kong 125
BD - Bangladesh 76
DE - Germania 55
FI - Finlandia 53
CA - Canada 46
IN - India 42
FR - Francia 39
PL - Polonia 28
GB - Regno Unito 26
NL - Olanda 22
JP - Giappone 21
AR - Argentina 20
TR - Turchia 20
BJ - Benin 19
IQ - Iraq 18
SE - Svezia 17
CI - Costa d'Avorio 16
RU - Federazione Russa 16
AT - Austria 15
BE - Belgio 15
MX - Messico 15
CL - Cile 13
KR - Corea 13
PE - Perù 13
CO - Colombia 12
ES - Italia 12
HN - Honduras 12
ID - Indonesia 12
GT - Guatemala 11
PK - Pakistan 11
ZM - Zambia 11
AE - Emirati Arabi Uniti 10
GR - Grecia 10
RO - Romania 10
UA - Ucraina 10
UY - Uruguay 10
ZA - Sudafrica 10
GA - Gabon 9
IE - Irlanda 9
JM - Giamaica 9
LB - Libano 9
MD - Moldavia 9
ML - Mali 9
NO - Norvegia 9
SA - Arabia Saudita 9
VE - Venezuela 9
BA - Bosnia-Erzegovina 8
CG - Congo 8
CR - Costa Rica 8
CZ - Repubblica Ceca 8
DO - Repubblica Dominicana 8
EC - Ecuador 8
LV - Lettonia 8
NI - Nicaragua 8
PH - Filippine 8
PS - Palestinian Territory 8
PY - Paraguay 8
AZ - Azerbaigian 7
BO - Bolivia 7
BS - Bahamas 7
CH - Svizzera 7
CU - Cuba 7
CV - Capo Verde 7
CW - ???statistics.table.value.countryCode.CW??? 7
EE - Estonia 7
GF - Guiana Francese 7
GH - Ghana 7
IL - Israele 7
JO - Giordania 7
UZ - Uzbekistan 7
BY - Bielorussia 6
CY - Cipro 6
DZ - Algeria 6
HR - Croazia 6
HU - Ungheria 6
IR - Iran 6
LY - Libia 6
MA - Marocco 6
PR - Porto Rico 6
TW - Taiwan 6
TZ - Tanzania 6
YT - Mayotte 6
GE - Georgia 5
GN - Guinea 5
KE - Kenya 5
LC - Santa Lucia 5
LT - Lituania 5
LU - Lussemburgo 5
MW - Malawi 5
MY - Malesia 5
NP - Nepal 5
TH - Thailandia 5
TN - Tunisia 5
ZW - Zimbabwe 5
Totale 4.315
Salva come PNG Salva come JPEG
Città #
Ashburn 342
San Jose 246
Singapore 246
Fairfield 119
Hong Kong 106
Chandler 89
Ho Chi Minh City 68
Los Angeles 67
Seattle 61
Hanoi 56
Beijing 53
Woodbridge 52
Houston 49
Council Bluffs 48
Wilmington 47
New York 46
Cambridge 43
Santa Clara 36
Ann Arbor 34
Helsinki 33
Chicago 27
Munich 26
São Paulo 23
Padova 22
Milan 21
Boardman 19
Buffalo 19
Da Nang 19
Cotonou 18
Abidjan 15
Montreal 15
Lauterbourg 14
Orem 14
Rome 14
Salt Lake City 14
Bytom 12
London 12
Princeton 12
The Dalles 12
Turku 12
Vienna 12
Lusaka 11
Medford 11
San Diego 11
Hefei 10
Tokyo 10
Warsaw 10
Bamako 9
Brussels 9
Dallas 9
Denver 9
Des Moines 9
Haiphong 9
Libreville 9
Montevideo 9
Nuremberg 9
Lappeenranta 8
Lima 8
Managua 8
Riga 8
Tampa 8
Toronto 8
Chennai 7
Johannesburg 7
Kingston 7
Nassau 7
San Pedro Sula 7
Seoul 7
Amman 6
Ankara 6
Baku 6
Dar es Salaam 6
Dublin 6
Erbil 6
Guatemala City 6
Prague 6
San José 6
Sterling 6
Willemstad 6
Accra 5
Castries 5
Chisinau 5
Conakry 5
Curitiba 5
Florence 5
Frankfurt am Main 5
Guangzhou 5
Havana 5
Jeddah 5
La Paz 5
Mexico City 5
Minsk 5
Nairobi 5
Ninh Bình 5
Phoenix 5
Porto Alegre 5
Praia 5
Redondo Beach 5
San Francisco 5
Somma Lombardo 5
Totale 2.598
Salva come PNG Salva come JPEG
Nome #
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 316
PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction 301
Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience 292
Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155) 276
Anaplastic Astrocytoma: State of the art and future directions 275
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 250
Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab 242
Mismatch-repair protein expression in high-grade gliomas: A large retrospective multicenter study 242
Myeloid Diagnostic and Prognostic Markers of Immune Suppression in the Blood of Glioma Patients 239
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study 233
Clinical management of diffuse low-grade gliomas 230
Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and Opportunities 227
Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study 227
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study 210
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series 203
The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation 200
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification 194
Patterns of gray and white matter functional networks involvement in glioblastoma patients: indirect mapping from clinical MRI scans 179
Indirect functional connectivity does not predict overall survival in glioblastoma 164
Totale 4.500
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.907
article - articoli 12.907
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.814
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022163 0 0 20 9 7 14 14 9 34 6 10 40
2022/2023154 27 22 5 17 21 14 2 11 24 4 6 1
2023/2024150 2 19 19 12 7 31 24 3 2 3 16 12
2024/2025604 2 30 21 15 44 23 20 50 64 59 138 138
2025/20262.822 164 212 307 487 263 115 448 168 317 139 108 94
2026/2027206 101 104 1 0 0 0 0 0 0 0 0 0
Totale 4.500